A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
P. Kerbrat,Riet Somers,Jaap Verweij,Derek Crowther,T. Tursz,Armando Santoro,W.P. Steward,M.A. Lentz,M. van Glabbeke,Henning T. Mouridsen +9 more
Journal ArticleDOI
Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma
Martin Dreyling,Panayiotis Panayiotidis,George A Follows,Luigina Mollica,Arnon Nagler,Muhit Ozcan,Armando Santoro,Don A. Stevens,David Trevarthen,Florian Hiemeyer,Li Liu,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +13 more
TL;DR: Cheson et al. as discussed by the authors reported results from 23 heavily pretreated patients with relapsed or refractory MZL treated with copanlisib from the Phase II CHRONOS-1 study.
Journal ArticleDOI
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Filippo de Braud,Christophe Dooms,Rebecca S. Heist,Céleste Lebbé,Martin Wermke,Anas Gazzah,Dirk Schadendorf,Piotr Rutkowski,Jürgen Wolf,Paolo A. Ascierto,Ignacio Gil-Bazo,Shumei Kato,Maria Wolodarski,Meredith Ann McKean,E. Muñoz Couselo,Martin Sebastian,Armando Santoro,Vesselina G. Cooke,Luca Manganelli,Kitty Wan,A. Gaur,Jaeyeon Kim,Giordano Caponigro,Xuan-Mai Couillebault,Helen Evans,Catarina D. Campbell,S. Basu,Michele Moschetta,Adil Daud +28 more
TL;DR: In this article , the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with NRAS-mutant melanoma.
Journal ArticleDOI
HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial.
Fabio Ciceri,Chiara Bonini,M.T. Lupo Stanghellini,Attilio Bondanza,Zulma Magnani,Serena K. Perna,Massimo Bernardi,Jacopo Peccatori,Alessandra Pescarollo,Paolo Servida,Fulvio Crippa,Luciano Callegaro,Monica Salomoni,Lucia Turchetto,Salvatore Toma,Paolo Bruzzi,L. Castagna,Armando Santoro,Jane F. Apperley,Shimon Slavin,Scialini Colombi,C. Gallo Stampino,M. Bregni,Claudio Bordignon +23 more
TL;DR: Results of a phase II multicenter trial of early add-backs of donor lymphocytes genetically engineered to express the herpes simplex thymidine kinase (TK) suicide gene after haplo-SCT confirm that TK-DLI is an effective tool for promoting immune reconstitution and protecting pts from late infectious mortality after haploing SCT.
Journal ArticleDOI
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo,Armando Santoro,Guillaume Cartron,Kiyoshi Ando,Javier Munoz,Steven Le Gouill,Koji Izutsu,Simon Rule,Pieternella J. Lugtenburg,Jia Ruan,Luca Arcaini,Marie-Laure Casadebaig,Brian A. Fox,Nurgul Kilavuz,Nils Rettby,Justine Dell’Aringa,Lilia Taningco,Richard Delarue,Myron S. Czuczman,Thomas E. Witzig +19 more
TL;DR: Exploratory biomarker analysis showed that response to durvalumab monotherapy or combination therapy was associated with higher interferon-γ signature scores in patients with follicular lymphoma, and durvalsumab alone or in combination appeared to add limited benefit to therapy.